Vir Biotechnology (VIR) announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta, CHD, demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus, HDV, RNA target not detected, TND, including those participants with cirrhosis and high baseline HDV RNA. The combination also showed alanine aminotransferase, ALT, reductions over time and a favorable safety profile. SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Earnings Call: Achievements and Challenges
- Positive Outlook for Vir Biotechnology: Buy Rating Driven by Promising Pipeline Developments and Strong Cash Position
- 3 Best Stocks to Buy Now, 11/6/2025, According to Top Analysts
- Vir Biotechnology’s Strategic Advancements in HDV and Oncology Programs Justify Buy Rating
- Vir Biotechnology: Strong Financials and Promising Clinical Developments Drive Buy Rating